Novartis Pauses Cell Therapy Study After Three Deaths
Pharmaceutical company Novartis halted eight clinical trials of its experimental cell therapy rap-cel following three deaths in August. The patients suffered severe, life-threatening immune reactions. The studies were intended for autoimmune and neurological disorders.